149 related articles for article (PubMed ID: 32142598)
1. Prediction of Clinical Transporter-Mediated Drug-Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models.
Carter SJ; Chouhan B; Sharma P; Chappell MJ
CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):211-221. PubMed ID: 32142598
[TBL] [Abstract][Full Text] [Related]
2. Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling.
Mitra P; Weinheimer S; Michalewicz M; Taub ME
Drug Metab Dispos; 2018 Jul; 46(7):953-963. PubMed ID: 29666154
[TBL] [Abstract][Full Text] [Related]
3. Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights.
Poulin P; Haddad S
J Pharm Sci; 2018 Jul; 107(7):1791-1797. PubMed ID: 29567347
[TBL] [Abstract][Full Text] [Related]
4. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model.
Neves DV; Vieira CP; Rocha A; Lanchote VL
J Pharm Pharm Sci; 2018; 21(1):236-246. PubMed ID: 29949502
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
Duan P; Zhao P; Zhang L
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
[TBL] [Abstract][Full Text] [Related]
7. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.
Fujino H; Nakai D; Nakagomi R; Saito M; Tokui T; Kojima J
Arzneimittelforschung; 2004; 54(7):382-8. PubMed ID: 15344842
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys.
Takahashi T; Ohtsuka T; Yoshikawa T; Tatekawa I; Uno Y; Utoh M; Yamazaki H; Kume T
Drug Metab Dispos; 2013 Oct; 41(10):1875-82. PubMed ID: 23929936
[TBL] [Abstract][Full Text] [Related]
9. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
[TBL] [Abstract][Full Text] [Related]
10. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach.
Vildhede A; Mateus A; Khan EK; Lai Y; Karlgren M; Artursson P; Kjellsson MC
Drug Metab Dispos; 2016 Apr; 44(4):505-16. PubMed ID: 26842596
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
13. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.
Chen Y; Zhang W; Huang WH; Tan ZR; Wang YC; Huang X; Zhou HH
Eur J Clin Pharmacol; 2013 Nov; 69(11):1933-8. PubMed ID: 23831870
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
Yoshikado T; Yoshida K; Kotani N; Nakada T; Asaumi R; Toshimoto K; Maeda K; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2016 Nov; 100(5):513-523. PubMed ID: 27170342
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
[TBL] [Abstract][Full Text] [Related]
16. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1.
Shirasaka Y; Suzuki K; Shichiri M; Nakanishi T; Tamai I
Drug Metab Pharmacokinet; 2011; 26(2):171-9. PubMed ID: 21206133
[TBL] [Abstract][Full Text] [Related]
17. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Zhang J; Thapar M; Farrell C; Wire MB
Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
Hirano M; Maeda K; Shitara Y; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
[TBL] [Abstract][Full Text] [Related]
19. Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Saleh MI; Melhim SB; Al-Ramadhani HM; Alzubiedi S
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):31-42. PubMed ID: 29948848
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability.
Chen J; Xu Y; Lou H; Jiang B; Shao R; Yang D; Hu Y; Ruan Z
Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):427-436. PubMed ID: 33779967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
